News

Filter

Current filters:

MetabolicsEurope

Novo Nordisk’s Saxenda gains EU approval for obesity

24-03-2015

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when, late in the day, the…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxendaVictoza

Sparse pipeline for acromegaly and gigantism treatment limiting market growth

03-02-2015

The acromegaly and gigantism treatment market will expand at a modest compound annual growth rate (CAGR)…

EuropeMarkets & MarketingMetabolicsNovartisPfizerPharmaceuticalSandostatin LARSigniforSomavertUSA

Rapid expansion forecast for global Cushing’s syndrome drug market

Rapid expansion forecast for global Cushing’s syndrome drug market

29-01-2015

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million…

CortendoEuropeHRA PharmaKetoconazoleMarkets & MarketingMetabolicsNormoCortNovartisPharmaceuticalRare diseasesSigniforUSA

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

23-01-2015

Danish diabetes care giant Novo Nordisk revealed yesterday that the European Medicines Agency’s Committee…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Back to top